Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway

Molecular Medicine Reports
Yong-Tao WuJian-Jun Gao

Abstract

Ewing's sarcoma (ES) is the second most common type of pediatric bone tumor, and is associated with a poor prognosis. Picropodophyllin (PPP), a novel selective inhibitor of insulin‑like growth factor‑1 receptor (IGF‑1R), is able to strongly inhibit various types of cancers. However, the effect of IGF‑1R on ES remains unclear. Following treatment with various concentrations of PPP for various times, cell viability was determined using an MTT assay. In addition, cell proliferation and apoptosis was investigated separately by bromodeoxyuridine staining and flow cytometry, respectively. The PPP‑associated signaling pathway was also investigated. The results of the present study suggested that PPP inhibited cell proliferation and viability of A673 and SK‑ES‑1 human Ewing's sarcoma cells in a dose- and time‑dependent manner. In addition, cell apoptosis rates were increased following treatment with PPP. Further investigation of the underlying mechanism revealed that PPP inhibited Akt phosphorylation. Fumonisin B1, an Akt‑specific activator, reversed the inhibitory effects of PPP on cell growth. Furthermore, the results suggested that PPP decreased the expression levels of IGF‑1R, a common activator of Akt signaling. PPP inhibited the ...Continue Reading

References

Sep 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E O BurgertP Thomas
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E de Alava, W L Gerald
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Katia ScotlandiPiero Picci
Jul 3, 2004·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Corinna Bähr, Bernd Groner
Dec 27, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roberto BiancoGiampaolo Tortora
Oct 10, 2006·Clinical & Experimental Metastasis·Kartik KrishnanLee J Helman
Nov 23, 2006·Molecular Cancer Research : MCR·Michelle KinseyStephen L Lessnick
Feb 3, 2007·Japanese Journal of Clinical Oncology·Yukihide Iwamoto
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria C ManaraKatia Scotlandi
May 1, 2009·PloS One·Maximilian KauerHeinrich Kovar
Mar 4, 2010·The Journal of Clinical Investigation·Anna RocchiKatia Scotlandi
Jun 11, 2010·Reviews on Recent Clinical Trials·Mary L HixonAntonio Gualberto
Aug 30, 2011·Cancer Genetics·Savita Sankar, Stephen L Lessnick
Feb 6, 2013·Skeletal Radiology·Natalia GorelikRobert Bleakney
May 15, 2013·Biochemical and Biophysical Research Communications·Xiaosheng LuJieqiang Lv
Aug 27, 2013·Biochemical and Biophysical Research Communications·Shu-Cheng YinZe-Zhang Tao
Jan 15, 2014·Cancer Research·Johannes FabianHedwig E Deubzer
Jan 21, 2014·Cytotherapy·Miguel Angel Martin-PiedraMiguel Alaminos
May 23, 2014·The Journal of Clinical Endocrinology and Metabolism·Sarah C BaumgartenCarlos Stocco

❮ Previous
Next ❯

Citations

Sep 24, 2016·Oncotarget·Deeksha VishwamitraHesham M Amin
Dec 7, 2017·Organic Letters·Saumen HajraSunit Hazra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis